Company intelligence / Profile preview

Avecris

Ownership: Private
Development stage: Preclinical

Overview

Avecris has developed a proprietary non‑viral genetic vector delivery system for next-generation gene therapy and vaccination. The company’s technology enables long-lasting and programmable gene expression with scalable, cell-free manufacturing. Clinical results are not yet available as the company remains pre-clinical but has established collaborations to advance its technology toward clinical development.

Therapeutic areas: OtherRare DiseasesInfectious Diseases
Modalities: Non-viral genetic vector delivery systems (dumbbell DNA vectors)RNA engineeringGenetic therapies and vaccines
Industry: Biotech

Partnerships

U.S. National Institute of Allergy and Infectious Diseases (NIAID) – advancing next-gen genetic vaccination technology together

Beyond the preview

Go deeper on Avecris.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avecris.

Explore the full profile